The Speed of Light–The ASTRO Foundation Innovation Awards 2027 provide up to $150,000 over two years for research advancing radiopharmaceutical therapy, also called radioligand therapy. This funding supports investigators in radiation oncology and radiation medicine working to improve treatment and patient outcomes.
The 2027 call welcomes projects exploring new therapeutic targets, differences between alpha- and beta-emitting agents, and combinations or sequencing with other treatments. Priority is given to research that produces practical resources or publications and creates opportunities for further funding.
Eligibility Criteria
- Applicants must be qualified investigators in radiation oncology or radiation medicine.
- Predoctoral students are ineligible.
- Residents and postdoctoral fellows must have a faculty mentor.
- Mentors must hold R01-level funding or equivalent and provide a support letter.
- Funds must be administered by an eligible US nonprofit or government-sponsored university, or a Canadian equivalent.
- Each applicant may submit only one application for this funding opportunity.
- Applicants may lead only one active Foundation research grant at a time.
- Comparable funding cannot cover the same research scope. speedoflightfoundation.org
Funding Details
- Amount: Typically $50,000–$150,000.
- Duration: Up to two years.
Deadline
- Letter of intent: November 23, 2026, according to the official webpage and RFP summary.
- Full proposal: February 22, 2027, by invitation.
- Award notification: Expected April 2027.
- Deadline clarification: The RFP’s application instructions separately state November 16 for LOIs. Applicants should confirm the deadline with the Foundation and prepare for the earlier date until clarified.
Further Information
- Official opportunity and complete guidelines
- Apply through ProposalCentral—filter by “Speed of Light – ASTRO.”
- Contact: SpeedOfLight@astro.org